Search research articles
Contact Us
Filters
Showing results (81-90 of 168) with videos related to
Page
of 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2009
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors
Gerald Batist, Karen A Gelmon, Kim N Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2004
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
Caio M Rocha Lima, Mark R Green, Robert Rotche, et al.
Critical Reviews in Oncology/Hematology
|
May 7, 2010
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study
Martine T E Puts, Johanne Monette, Veronique Girre, et al.
Toxicology Letters
|
August 23, 2005
Antimony trioxide-induced apoptosis is dependent on SEK1/JNK signaling
Koren K Mann, Kelly Davison, Myrian Colombo, et al.
Oncoimmunology
|
February 24, 2026
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma
Caroline Lambert, Rahima Jamal, Paméla Thébault, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2003
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
Manijeh Daneshmand, Doris A E Parolin, Holger W Hirte, et al.
Elife
|
November 8, 2017
The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity
Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Audrey Emond, et al.
Cell Reports
|
March 30, 2022
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade
Nivine Srour, Oscar D Villarreal, Swanand Hardikar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2017
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Teresa M Petrella, Caroline Robert, Erika Richtig, et al.
Nature Communications
|
October 19, 2019
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
Khashayar Esfahani, Tho-Alfakar Al-Aubodah, Pamela Thebault, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 168) with videos related to
Sort By:
Page
of 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 17, 2009
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors
Gerald Batist, Karen A Gelmon, Kim N Chi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 15, 2004
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate
Caio M Rocha Lima, Mark R Green, Robert Rotche, et al.
Critical Reviews in Oncology/Hematology
|
May 7, 2010
Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study
Martine T E Puts, Johanne Monette, Veronique Girre, et al.
Toxicology Letters
|
August 23, 2005
Antimony trioxide-induced apoptosis is dependent on SEK1/JNK signaling
Koren K Mann, Kelly Davison, Myrian Colombo, et al.
Oncoimmunology
|
February 24, 2026
A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma
Caroline Lambert, Rahima Jamal, Paméla Thébault, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2003
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients
Manijeh Daneshmand, Doris A E Parolin, Holger W Hirte, et al.
Elife
|
November 8, 2017
The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity
Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Audrey Emond, et al.
Cell Reports
|
March 30, 2022
PRMT7 ablation stimulates anti-tumor immunity and sensitizes melanoma to immune checkpoint blockade
Nivine Srour, Oscar D Villarreal, Swanand Hardikar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 9, 2017
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
Teresa M Petrella, Caroline Robert, Erika Richtig, et al.
Nature Communications
|
October 19, 2019
Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
Khashayar Esfahani, Tho-Alfakar Al-Aubodah, Pamela Thebault, et al.
Page
of 17